원문정보
초록
영어
Human milk oligosaccharides (HMOs) have been proven to be a key ingredient found in breast milk and beneficial to infant health. Structurally, the fucose-containing oligosaccharides are major components, with a proportion of approximately 50–80% in the HMOs. In particular, 2-fucosyllactose (2’-FL) and 3-fucosyllactose (3-FL) are 2 major components of the abundant HMO component. Importantly, 2’-FL is approved for use in infant formula for improving probiotic functions by the FDA of the USA and the European Food Safety Authority, while 3-FL can be used as a prebiotic to improve the growth of beneficial microorganisms. Over the last decade, various approaches have been conducted for fucosyllactose (FL) production, including chemical synthesis, enzymatic conversion, and microbial fermentation. Most studies were performed in Escherichia coli due to the simple culture conditions and availability of various genetic tools. Besides E. coli, Bacillus subtilis and Saccharomyces cerevisiae have also been selected as the hosts for the production of FL due to their generally regarded safe (GRAS) status. As a type of GRAS strain, Corynebacterium glutamicum has been widely used in the biosynthesis of food-grade, high-value-added products, including lysine, glutamic acid, violacein and resveratrol. In this study, the biosynthetic enzymes of FL were condon-optimized and heterologously expressed in engineered C. glutamicum for the production of FL. The trace amount production of FL was confirmed by TLC, HPLC in this study.